BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance.Nat Rev Gastroenterol Hepatol. 2020;17:1-2. [PMID: 31520081 DOI: 10.1038/s41575-019-0211-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao M, Yang C, Wu C, Chen Y, Zhuang H, Wang J, Cao Z. Hydrogel-metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis. J Nanobiotechnology 2022;20:404. [PMID: 36064365 DOI: 10.1186/s12951-022-01603-6] [Reference Citation Analysis]
2 Sood A, Singh A, Mahajan R, Midha V, Bernstein CN, Rubin DT. (Re)Appraising Remission in Ulcerative Colitis. Inflamm Bowel Dis 2022:izac170. [PMID: 35917172 DOI: 10.1093/ibd/izac170] [Reference Citation Analysis]
3 Liu S, Cao Y, Ma L, Sun J, Ramos-Mucci L, Ma Y, Yang X, Zhu Z, Zhang J, Xiao B. Oral antimicrobial peptide-EGCG nanomedicines for synergistic treatment of ulcerative colitis. J Control Release 2022:S0168-3659(22)00288-7. [PMID: 35580812 DOI: 10.1016/j.jconrel.2022.05.025] [Reference Citation Analysis]
4 Taxonera C, Fernández-Aceñero MJ, Olivares D, Calvo M, Casis B, Bermejo F, López Serrano P, Iborra M, Mesonero F, Boscá Watts M, Díaz Del Arco C, Vera I, Olivares S, Algaba A, Alba C. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2022. [PMID: 35509152 DOI: 10.1111/apt.16964] [Reference Citation Analysis]
5 Seong G, Song JH, Kim JE, Kim TJ, Kim ER, Hong SN, Chang DK, Kim SH, Ha SY, Kim YH. Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1. Inflamm Bowel Dis 2022:izac075. [PMID: 35396998 DOI: 10.1093/ibd/izac075] [Reference Citation Analysis]
6 Wang R, Guo K, zhang W, He Y, Yang K, Chen Q, Yang L, Di Z, Qiu J, Lei P, Gu Y, Luo Z, Xu X, Xu Z, Feng X, Li S, Yu Z, Xu H. Poly‐γ‐Glutamic Acid Microgel‐Encapsulated Probiotics with Gastric Acid Resistance and Smart Inflammatory Factor Targeted Delivery Performance to Ameliorate Colitis. Adv Funct Materials. [DOI: 10.1002/adfm.202113034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Vespa E, D’amico F, Sollai M, Allocca M, Furfaro F, Zilli A, Dal Buono A, Gabbiadini R, Danese S, Fiorino G. Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. JCM 2022;11:939. [DOI: 10.3390/jcm11040939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ma Y, Duan L, Sun J, Gou S, Chen F, Liang Y, Dai F, Xiao B. Oral nanotherapeutics based on Antheraea pernyi silk fibroin for synergistic treatment of ulcerative colitis. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Taylor Meadows K, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Aliment Pharmacol Ther 2022. [PMID: 35014040 DOI: 10.1111/apt.16753] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
10 Grimstad T, Skjellerudsveen BM, Kvaløy JT, Skoie IM, Carlsen A, Karlsen LN, Aabakken L, Omdal R. The influence of disease activity on fatigue in patients with ulcerative colitis - a longitudinal study. Scand J Gastroenterol 2021;:1-8. [PMID: 34846950 DOI: 10.1080/00365521.2021.2007281] [Reference Citation Analysis]
11 Vaishnav M, Elhence A, Biswas S, Pathak P, Anand A, Sheikh S, Singh V, Maitra S, Goel A, Shalimar. The Outcome after Hospital Discharge in Cirrhosis is Not Worsened with COVID-19 Infection: A Propensity Score-matched Analysis. J Clin Exp Hepatol 2021. [PMID: 34840484 DOI: 10.1016/j.jceh.2021.11.009] [Reference Citation Analysis]
12 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2021:izab228. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Correia FP, Lourenço LC. Artificial intelligence application in diagnostic gastrointestinal endoscopy - Deus ex machina? World J Gastroenterol 2021; 27(32): 5351-5361 [PMID: 34539137 DOI: 10.3748/wjg.v27.i32.5351] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Song F, Zhang Y, Pan Z, Hu X, Zhang Q, Huang F, Ye X, Huang P. The role of alcohol dehydrogenase 1C in regulating inflammatory responses in ulcerative colitis. Biochem Pharmacol 2021;192:114691. [PMID: 34293286 DOI: 10.1016/j.bcp.2021.114691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ferrante M, Sabino J. Efficacy of JAK inhibitors in Ulcerative Colitis. J Crohns Colitis 2020;14:S737-45. [PMID: 31879750 DOI: 10.1093/ecco-jcc/jjz202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
16 Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6:589-95. [PMID: 34019798 DOI: 10.1016/S2468-1253(21)00065-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
17 Su S, Wang X, Xi X, Zhu L, Chen Q, Zhang H, Qin Y, Yang B, Che N, Cao H, Zhong W, Wang B. Phellodendrine promotes autophagy by regulating the AMPK/mTOR pathway and treats ulcerative colitis. J Cell Mol Med 2021;25:5707-20. [PMID: 34002930 DOI: 10.1111/jcmm.16587] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
18 Panés J, Vermeire S, Dubinsky MC, Loftus EV, Lawendy N, Wang W, Salese L, Su C, Modesto I, Guo X, Colombel JF. Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: Results From the OCTAVE Clinical Trials. J Crohns Colitis 2021:jjab065. [PMID: 33884415 DOI: 10.1093/ecco-jcc/jjab065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 D'Amico F, Guillo L, Baumann C, Danese S, Peyrin-Biroulet L. Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis. J Crohns Colitis 2021:jjab063. [PMID: 33822915 DOI: 10.1093/ecco-jcc/jjab063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Du Y, Rong L, Cong Y, Shen L, Zhang N, Wang B. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease. Expert Opin Ther Targets 2021;25:191-209. [PMID: 33682588 DOI: 10.1080/14728222.2021.1901079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, Danese S. 'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. Curr Drug Targets 2021;22:117-25. [PMID: 32718289 DOI: 10.2174/1389450121666200727120305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Cui J, Li Y, Jiao C, Gao J, He Y, Nie B, Kong L, Guo W, Xu Q. Improvement of magnesium isoglycyrrhizinate on DSS-induced acute and chronic colitis. Int Immunopharmacol 2021;90:107194. [PMID: 33290965 DOI: 10.1016/j.intimp.2020.107194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
23 Popa IV, Burlacu A, Mihai C, Prelipcean CC. A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor α Agents. Medicina (Kaunas) 2020;56:E628. [PMID: 33233514 DOI: 10.3390/medicina56110628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 van der Laan JJH, van der Waaij AM, Gabriëls RY, Festen EAM, Dijkstra G, Nagengast WB. Endoscopic imaging in inflammatory bowel disease: current developments and emerging strategies. Expert Rev Gastroenterol Hepatol 2021;15:115-26. [PMID: 33094654 DOI: 10.1080/17474124.2021.1840352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
25 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
26 Thierry AR, Roch B. Neutrophil Extracellular Traps and By-Products Play a Key Role in COVID-19: Pathogenesis, Risk Factors, and Therapy. J Clin Med 2020;9:E2942. [PMID: 32933031 DOI: 10.3390/jcm9092942] [Cited by in Crossref: 28] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
27 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
28 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
29 Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? J Clin Med 2020;9:E2646. [PMID: 32823997 DOI: 10.3390/jcm9082646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Thierry AR. Host/genetic factors associated with COVID-19 call for precision medicine. Precision Clinical Medicine 2020;3:228-34. [DOI: 10.1093/pcmedi/pbaa026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]
31 Quaresma AB, Yamamoto T, Kotze PG. Biologics and surgical outcomes in Crohn's disease: is there a direct relationship? Therap Adv Gastroenterol 2020;13:1756284820931738. [PMID: 32728389 DOI: 10.1177/1756284820931738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
32 Thierry A, Roch B. SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure. Clinical Science 2020;134:1295-300. [DOI: 10.1042/cs20200531] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
33 Ben Nessib D, Ferjani H, Maatallah K, Rahmouni S, Kaffel D, Hamdi W. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Clin Rheumatol 2020;39:3543-53. [PMID: 32424656 DOI: 10.1007/s10067-020-05136-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Pugliese N, Roda G, Peyrin-biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2020;25:71-9. [DOI: 10.1080/14728214.2020.1737009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
35 Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opin Biol Ther 2020;20:407-12. [PMID: 31847610 DOI: 10.1080/14712598.2020.1701652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]